يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Iacoboni G."', وقت الاستعلام: 0.64s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

    المؤلفون: Hutchings, M, Morschhauser, F, Iacoboni, G, Carlo-Stella, C, Offner, FC, Sureda, A, Salles, G, Martinez-Lopez, J, Crump, M, Thomas, DN, Morcos, PN, Ferlini, C, Broeske, A-ME, Belousov, A, Bacac, M, Dimier, N, Carlile, DJ, Lundberg, L, Perez-Callejo, D, Umana, P, Moore, T, Weisser, M, Dickinson, MJ

    العلاقة: Hutchings, M., Morschhauser, F., Iacoboni, G., Carlo-Stella, C., Offner, F. C., Sureda, A., Salles, G., Martinez-Lopez, J., Crump, M., Thomas, D. N., Morcos, P. N., Ferlini, C., Broeske, A. -M. E., Belousov, A., Bacac, M., Dimier, N., Carlile, D. J., Lundberg, L., Perez-Callejo, D. ,. Dickinson, M. J. (2021). Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. JOURNAL OF CLINICAL ONCOLOGY, 39 (18), pp.1959-+. https://doi.org/10.1200/JCO.20.03175Test.; http://hdl.handle.net/11343/288764Test

    الإتاحة: https://doi.org/10.1200/JCO.20.03175Test
    http://hdl.handle.net/11343/288764Test

    View record in BASE

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    P1458: PATTERNS OF LONG‐TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19‐DIRECTED CAR T‐CELL THERAPY FOR R/R LBCL.

    المؤلفون: Rejeski, K., Albanyan, O., Iacoboni, G., Bücklein, V., Blumenberg, V., Penack, O., Bethge, W., Völkl, S., Perez, A., Carpio, C., Schmidt, C., Müller, N., Reid, K., Faramand, R., Davila, M., Bullinger, L., Locke, F., von Bergwelt‐Baildon, M., Mackensen, A., Barba, P.

    المصدر: HemaSphere; 2022 Supplement 3, Vol. 6, p1340-1341, 2p

    النص الكامل

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER CD19 CAR T‐CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE.

    المؤلفون: Bücklein, V., Perez, A., Iacoboni, G., Rejeski, K., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., Frölich, L., Johnson, G., Patel, K., Arciola, B., Schmidt, C., Albanyan, O., Gödel, P., Hoster, E., Bullinger, L., Mackensen, A., Locke, F.

    المصدر: HemaSphere; 2022 Supplement 3, Vol. 6, p1330-1331, 2p

    النص الكامل

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    S261: SAFETY AND PRELIMINARY EFFICACY FINDINGS OF AUTO4, A TRBC1‐TARGETTING CAR, IN RELAPSED/REFRACTORY TRBC1 POSITIVE SELECTED T CELL NON‐HODGKIN LYMPHOMA.

    المؤلفون: Cwynarski, K., Tholouli, E., Iacoboni, G., Menne, T., Irvine, D., Wood, L., Balasubramaniam, N., Shang, J., Zhang, M, Duffy, K., Huber, B., Vinson, M., Brugger, W., Pule, M.

    المصدر: HemaSphere; 2022 Supplement 3, Vol. 6, p162-163, 2p

    النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS.

    المؤلفون: Dickinson, M., Carlo‐Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., Wu, S.‐J., Cartron, G., Hertzberg, M., Sureda, A., Perez‐Callejo, D., Lundberg, L., Relf, J., Clark, E., Humphrey, K., Hutchings, M.

    المصدر: HemaSphere; 2022 Supplement 3, Vol. 6, p121-122, 2p

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث